Long-acting HIV regimen a ‘game changer’ preferred by most patients

SEATTLE — Long-acting cabotegravir plus rilpivirine administered every 2 months was noninferior to daily oral HIV medication and was preferred by most participants in a phase 3b randomized trial, according to data presented here.
“The treatment needs of people living with HIV are changing, with ample evidence on patient preference suggesting some people living with HIV can experience challenges with taking daily oral treatment for HIV,” Harmony P. Garges, MD, MPH, chief medical officer for ViiV Healthcare, which markets the FDA-approved long-acting Cabenuva, said in a press

SEATTLE — Long-acting cabotegravir plus rilpivirine administered every 2 months was noninferior to daily oral HIV medication and was preferred by most participants in a phase 3b randomized trial, according to data presented here.
“The treatment needs of people living with HIV are changing, with ample evidence on patient preference suggesting some people living with HIV can experience challenges with taking daily oral treatment for HIV,” Harmony P. Garges, MD, MPH, chief medical officer for ViiV Healthcare, which markets the FDA-approved long-acting Cabenuva, said in a press